Literature DB >> 15986423

Dystonia and parkinsonism in GM1 type 3 gangliosidosis.

Emmanuel Roze1, Eduard Paschke, Nathalie Lopez, Thomas Eck, Kunihiro Yoshida, Annie Maurel-Ollivier, Diane Doummar, Catherine Caillaud, Damien Galanaud, Thierry Billette de Villemeur, Marie Vidailhet, Anne Roubergue.   

Abstract

GM1 gangliosidosis is due to beta-galactosidase deficiency. Only patients with type 3 disease survive into adulthood and develop movement disorders. Clinical descriptions of this form are rare, particularly in non-Japanese patients. We describe four new patients and systematically analyze all previous reports found by a literature search and contacts with the authors for additional information. Generalized dystonia remained the predominant feature throughout the disease course and was often associated with akinetic-rigid parkinsonism. GM1 gangliosidosis must be considered as a cause of early-onset generalized dystonia, particularly in patients with short stature and skeletal dysplasia. Copyright (c) 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986423     DOI: 10.1002/mds.20593

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  30 in total

1.  β-Galactosidosis in Patient with Intermediate GM1 and MBD Phenotype.

Authors:  Tereza Moore; Jonathan A Bernstein; Sylvie Casson-Parkin; Tina M Cowan
Journal:  JIMD Rep       Date:  2012-04-22

2.  Clinical Findings and Natural History in Ten Unrelated Families with Juvenile and Adult GM1 Gangliosidosis.

Authors:  João Stein Kannebley; Laura Silveira-Moriyama; Laís Orrico Donnabella Bastos; Carlos Eduardo Steiner
Journal:  JIMD Rep       Date:  2015-06-25

Review 3.  The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy.

Authors:  Debra S Regier; Richard L Proia; Alessandra D'Azzo; Cynthia J Tifft
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

4.  Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.

Authors:  Katrin M Fantur; Tanja M Wrodnigg; Arnold E Stütz; Bettina M Pabst; Eduard Paschke
Journal:  J Inherit Metab Dis       Date:  2011-10-28       Impact factor: 4.982

Review 5.  Parkinsonism and inborn errors of metabolism.

Authors:  A Garcia-Cazorla; S T Duarte
Journal:  J Inherit Metab Dis       Date:  2014-06-07       Impact factor: 4.982

Review 6.  Modeling neuronopathic storage diseases with patient-derived culture systems.

Authors:  Friederike Zunke; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2019-02-19       Impact factor: 5.996

Review 7.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

8.  Beta-galactosidase deficiencies and novel GLB1 mutations in three Chinese patients with Morquio B disease or GM1 gangliosidosis.

Authors:  Hong-Lin Lei; Jun Ye; Wen-Juan Qiu; Hui-Wen Zhang; Lian-Shu Han; Yu Wang; Xue-Fan Gu
Journal:  World J Pediatr       Date:  2012-11-15       Impact factor: 2.764

Review 9.  Lysosomal storage diseases.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-05-25

10.  An insight into the biochemistry of inborn errors of metabolism for a clinical neurologist.

Authors:  Rita Christopher; Bindu P Sankaran
Journal:  Ann Indian Acad Neurol       Date:  2008-04       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.